Suven Life Sciences Limited — Others, 15-05-2025: Monitoring Agency Report

Suven Life Sciences has announced a board meeting to review the financial results for the quarter and half-year. The company has fully utilized the Rs 397 Cr raised from its Rights Issue, allocating Rs 250 Cr to pharmaceutical R&D and clinical trials, Rs 50 Cr to repay an inter-corporate deposit, and about Rs 97 Cr for general corporate purposes including business growth. Fund usage aligns with prior disclosures and supports the company’s strategic growth and operational plans, with no delays or deviations.